Favourable humoral but reduced cellular immune response to COVID-19 mRNA BNT162b2 vaccine in patient...
Favourable humoral but reduced cellular immune response to COVID-19 mRNA BNT162b2 vaccine in patients with childhood-onset systemic lupus erythematosus
About this item
Full title
Author / Creator
Publisher
England: Lupus Foundation of America
Journal title
Language
English
Formats
Publication information
Publisher
England: Lupus Foundation of America
Subjects
More information
Scope and Contents
Contents
ObjectiveTo evaluate both humoral and cellular immune responses to the COVID-19 messenger RNA (mRNA; BNT162b2) vaccine in patients with childhood-onset SLE (cSLE) compared with healthy controls and patient controls (kidney transplant (KTx) recipients).MethodsThis single-centre, cross-sectional and case–control study included 16 patients with cSLE,...
Alternative Titles
Full title
Favourable humoral but reduced cellular immune response to COVID-19 mRNA BNT162b2 vaccine in patients with childhood-onset systemic lupus erythematosus
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d25527ea6ea24c6ba3b4a569d8588519
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d25527ea6ea24c6ba3b4a569d8588519
Other Identifiers
ISSN
2053-8790
E-ISSN
2053-8790
DOI
10.1136/lupus-2024-001268
